Isatuximab and Belantamab Mafodotin: A Primer to an Evolving Multiple Myeloma Landscape
As the second most common haematological malignancy, multiple myeloma (MM), a plasma cell disorder, continues to affect a significant portion of patients with increasing incidence over the past 25 years…